ADCT 8-K Attaches Q2 2025 Financial Results Press Release (Exhibit 99.1)

Rhea-AI Filing Summary

ADC Therapeutics SA reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company filed a Current Report on Form 8-K to attach that press release as Exhibit 99.1, and the filing also includes a Cover Page Interactive Data File as Exhibit 104.

The filing states that the information in Item 2.02 and Exhibit 99.1 is incorporated by reference but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The report is signed on behalf of the company by Jose Carmona, Chief Financial Officer. The 8-K itself does not include the detailed financial tables or results within the body of the filing.

Positive

• The company attached a press release announcing financial results for the quarter ended June 30, 2025 as Exhibit 99.1 to the 8-K.
• The filing includes an interactive Cover Page XBRL file as Exhibit 104, indicating structured data is provided.

Negative

• The Form 8-K does not include the actual financial results within the filing text; substantive numbers must be obtained from Exhibit 99.1.
• The registrant explicitly states that Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, limiting Section 18 liability.

Insights

Securities Analyst

TL;DR: ADC attached its Q2 2025 results press release to an 8-K; the release is disclosed but not legally "filed" under Section 18.

The 8-K is a routine disclosure mechanism to ensure the market has access to the company’s Q2 2025 results via Exhibit 99.1. Because the company explicitly states the press release is not "filed" under Section 18, investors should treat the exhibit as furnished disclosure rather than a filing that creates Section 18 liabilities. The document provides no numeric results in the 8-K text itself, so stakeholders must review Exhibit 99.1 for the substantive financial metrics.

Corporate Governance Expert

TL;DR: This 8-K reflects standard disclosure practice and reiterates legal limits on liability for the attached press release.

The Form 8-K attaches a press release as Exhibit 99.1 and includes customary boilerplate that the exhibit is not "filed" under the Exchange Act. The filing establishes a public record of the release and is signed by the CFO, reflecting compliance with disclosure procedures. There are no governance changes, officer departures, or material transactions reported in this filing.

false000177191000017719102025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 12, 2025

ADC Therapeutics SA

(Exact Name of Registrant as Specified in Its Charter)

Switzerland (State or Other Jurisdiction of Incorporation)			001-39071 (Commission File Number)						N/A (IRS Employer Identification Number)
Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code)						+41 21 653 02 00 (Registrant’s Telephone Number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class			Trading Symbol			Name of Each Exchange on Which Registered
Common Shares, par value CHF 0.08 per share			ADCT			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 12, 2025, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number			Description
99.1			Press Release dated August 12, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ADC Therapeutics SA
Date: August 12, 2025
			By:			/s/ Jose Carmona
			Name:			Jose Carmona
			Title:			Chief Financial Officer

FAQ

What did ADC Therapeutics (ADCT) disclose in this 8-K?

The company attached a press release announcing its financial results for the quarter ended June 30, 2025 as Exhibit 99.1 and included Exhibit 104 for interactive data.

Is the press release attached to ADCT's 8-K considered "filed"?

No. The filing states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Where can investors find the detailed Q2 2025 results for ADCT?

Detailed financial results are contained in the press release attached as Exhibit 99.1; the 8-K text itself does not include the numeric results.

On which exchange are ADC Therapeutics' common shares listed?

ADC Therapeutics' common shares trade under the symbol ADCT on the New York Stock Exchange.

What is ADC Therapeutics' jurisdiction of incorporation?

The registrant is incorporated in Switzerland.

Who signed the 8-K on behalf of ADC Therapeutics?

The 8-K is signed on behalf of the registrant by Jose Carmona, Chief Financial Officer.